lilly glp 1 agonist is now pharma's top revenue company. It just got FDA approval for an oral GLP-1, but Wall Street isn't celebrating FDA approves Lilly's Foundayo (orforglipron)
Description
But weight loss denials are different
Stevens-Johnson syndrome induced by tonic water
This is a testament to the power of a sustained, long-term approach
doi: 10.2337/dc12-2454 51 WildingJPHBatterhamRLCalannaSDaviesMVan GaalLFLingvayIet al
The administration of liraglutide was associated with a significantly decreased risk of incident bone fractures (MH-OR: 0.38, 95% CI: 0.17-0.87), while exenatide administration was linked with an increased risk (MH-OR: 2.09, 95% CI: 1.03-4.21)
